Business Context and Reporting Period
This Form 8-K reports on events occurring on June 3, 2025, regarding TNF Pharmaceuticals, Inc. (TNFA). The filing details the reconvened 2025 Annual Meeting of Stockholders, originally adjourned from May 20, 2025. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure amendments. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to increase authorized common stock from 250,000,000 to 1,250,000,000 shares. The amendment was filed with the Delaware Secretary of State on June 6, 2025.
- Preferred Stock Stated Value: Stockholders authorized the Board to increase the stated value of Series F and Series F-1 Convertible Preferred Stock from $1,000 to up to $1,125 per share. Consequently, the Series F stated value automatically increased to $1,100 per share effective January 1, 2025.
- Reverse Stock Split Authorization: Stockholders approved a proposal authorizing the Board to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-100 within one year of approval.
- Director Elections: Six directors were re-elected for one-year terms: Mitchell Glass, Christopher C. Schreiber, Joshua Silverman, Jude Uzonwanne, Bill J. White, and Stephen Friscia.
- Auditor Ratification: Stephano Slack LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting Results and Capital Structure
As of the record date (March 25, 2025), the voting power was distributed as follows:
- Common Stock: 7,392,565 shares outstanding.
- Series D Preferred: 72,992 shares (1,217 votes).
- Series F Preferred: ~3,839.35 shares (~62,294 votes).
- Series F-1 Preferred: 2,529.71 shares (1,124,314 votes).
- Series G Preferred: 8,565 shares (3,806,665 votes).
All six proposals submitted to the vote were approved. Notably, the Reverse Stock Split proposal received 6,419,725 votes for and 846,410 against. The Share Increase Amendment received 6,304,950 votes for and 923,764 against.
Outlook, Risks, and Contingencies
The filing does not contain specific management commentary on future financial outlook or operational risks. However, the approval of a reverse stock split (1-for-2 to 1-for-100) suggests the company may be addressing share price levels or exchange listing requirements. The increase in authorized shares provides flexibility for future capital raises or corporate transactions.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio once determined by the Board, as it is currently discretionary between 1-for-2 and 1-for-100.
- Confirm the impact of the increased stated value of Series F Preferred Stock ($1,100) on the company's balance sheet and potential conversion dilution.
- Review the definitive proxy statement (Schedule 14A) for detailed rationale behind the capital structure changes.
- Monitor subsequent filings for the execution of the reverse stock split and any new issuances under the expanded authorized share count.